Excellus BlueCross BlueShield partnering with Civica to increase access to affordable insulin

Posted on March 2, 2022

News Release

 

For Immediate Release                                                                                 Contact: Karen Feigel

Date: March 3, 2022                                                                                                       (585) 238-4308


Excellus BlueCross BlueShield partnering with Civica

to increase access to affordable insulin

Civica to manufacture and distribute three insulins for $30 or less per vial


ROCHESTER, NY - Today, Excellus BlueCross BlueShield, the Blue Cross Blue Shield Association (BCBSA) and other Blue Cross and Blue Shield (BCBS) companies joined Civica’s initiative to manufacture and distribute affordable insulins that, once approved, will be available to people living with diabetes at significantly lower prices than insulins currently on the market. The medications are expected to be available to all consumers for $30 or less per vial starting in 2024.

 

Excellus BCBS, BCBSA and BCBS companies are collaborating on this initiative with Civica and other partners across the health care industry, representing nearly every corner of the diabetes ecosystem.

 

“We’re proud to be part of this national collaboration to bring more affordable insulin and other medications to our communities,” said Mona Chitre, Pharm.D., chief pharmacy officer and vice president of Integrated Health Strategy for Excellus BCBS. “The Civica initiative will help us fulfill our critical role of controlling rising health care costs while also ensuring that more patients take their medication as prescribed since their prescription drugs will now be more affordable.”

 

“This is an important milestone in our continued partnership with Civica as we advance our shared goal of bringing lower-cost prescription medication directly to consumers,” said Kim Keck, president and CEO of BCBSA. “Access to affordable insulin can be the difference between life and death for diabetics – and we’re proud to be a part of Civica’s effort to ensure that millions of Americans have access to the medicine they need at a price they can afford. When we come together, we can make health care more affordable.”

More than eight million Americans rely on insulin to live, but as many as one in four insulin users report having to skip doses or take less than prescribed amounts due to the high cost of the medicine.[1] The financial burden has made the drug inaccessible for many and has led to patients developing health conditions that were once preventable.

 

Through this initiative, Civica will manufacture and distribute three analog insulins – glargine, lispro and aspart – which will be biosimilar drugs of the brand-name insulins Lantus, Humalog and Novolog. The insulins will be available in vials and prefilled pens at no more than $30 per vial or $55 for a box of five pens.

 

“Diabetes is arguably America’s most expensive chronic condition, and it is heartbreaking that millions

 

–more–

 

News release: Excellus BlueCross BlueShield Partnering with Civica – page 2

 

of people are rationing their care and putting their lives at risk because they can no longer afford insulin,” said Dan Liljenquist, board chair of Civica. “Through mission-driven partnerships, we are choosing to create a new market reality where no one is forced to ration essential diabetes medications.”

 

This insulin initiative is one of the many ways BCBS companies are partnering with Civica to increase access to safe and affordable medications. This announcement follows the founding of Civica’s subsidiary, CivicaScript, by BCBSA, 18 BCBS companies and Civica Rx to develop and manufacture common generic medications for which there is currently not enough market competition to drive down prices. The first of these lower-cost generic prescriptions are expected to be available to consumers through specialty and home delivery pharmacies later this year.

 

For more information on the insulin initiative, visit https://civicainsulin.org. For more information on CivicaScript, visit: https://www.bcbs.com/civica-rx.

 

 

###

 

About Excellus BlueCross BlueShield
Excellus BlueCross BlueShield, an independent licensee of the Blue Cross Blue Shield Association, is a nonprofit health plan with 1.5 million upstate New York members. The company's mission is to help people live healthier and more secure lives through access to high-quality, affordable health care. Its products and services include cost-saving prescription drug discounts, wellness tracking tools and access to telemedicine. With more than 3,500 employees, the company is committed to attracting and retaining a diverse workforce to foster innovation and better serve its members. It also encourages employees to engage in their communities by providing paid volunteer time off as one of many benefits. To learn more, visit
ExcellusBCBS.com.

About the Blue Cross Blue Shield Association
The Blue Cross and Blue Shield Association is a national federation of 34 independent, community-based and locally operated Blue Cross and Blue Shield companies that collectively provide health care coverage for one in three Americans.

[1] JAMA, Cost-Related Insulin Underuse Among Patients with Diabetes, 2019

Other Member News

Larry Bousquet
July 16, 2024

Crouse Health Board of Directors Welcomes Two New Members

The Crouse Health Board of Directors has appointed two new directors.

SUNY Press Release: SUNY Chancellor King Announces Launch of $6 Million Upstate Biotech Ventures
July 16, 2024

SUNY Chancellor King Announces Launch of $6 Million Upstate Biotech Ventures

Upstate Biotech Ventures will invest in Startups and Small Businesses affiliated with Upstate Medical University to drive research and technology innovation.

Home Buyer Seminar
July 15, 2024

Sidney Federal Credit Union Home Buying Seminar

Join us for an information packed hour, designed to help you navigate the mortgage process with confidence!

Impel Acquires Automotive Customer Engagement Platform Outsell in $100M+ Deal
July 15, 2024

Impel Acquires Automotive Customer Engagement Platform Outsell in $100M+ Deal

Adding Outsell’s data-driven outreach capabilities to Impel AI creates the auto industry’s first end-to-end global AI sales and marketing automation platform.

July 15, 2024

Patenting Biotechnology: CRISPR, Antibodies, Diagnostics, and Protein Based Biomaterials

The basic concepts of intellectual property law will be introduced.

Danyel Akins-Barbara Clark_Solvay Bank New Hires
July 12, 2024

Solvay Bank Announces Two Recent Hires

Solvay Bank, the oldest community bank established in Onondaga County, is pleased to welcome two recent hires to its team: Danyel Akins and Barbara Clark.

Harris Beach
July 12, 2024

Harris Beach and Murtha Cullina Partners Approve New Operating Agreement for Combined Firm

Both firms have approved an Operating Agreement that will govern a new, combined firm to be known as Harris Beach Murtha.

July 12, 2024

The Illusionists - Magic of the Holidays are Coming to the Landmark Theatre Thursday, Nov. 21 at 7:30 p.m.

Celebrate the holidays with the entire family at The Illusionists – Magic of the Holidays, a mind-blowing showcase featuring jaw-dropping talents of the most incredible illusionists on earth.

Tompkins Community Bank
July 12, 2024

Tompkins Community Bank Welcomes Taryn Schwartz as Residential Mortgage Originator

Schwartz will work with buyers across the Central New York region to achieve their ultimate goal of being homeowners.